You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia

    SBC: MICROFLUIDIC INNOVATIONS, LLC            Topic: 102

    DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Algorithm to Identify Patients at Risk of Medication-Related Hospitalization

    SBC: L. KRENK, INC.            Topic: R

    The long range goal of this fast track research application is to improve healthcare quality and reduce healthcare costs nationwide among those at risk for medication related hospitalizationThe specific objective of this proposed research is to develop an algorithm that uses existing electronic health information to efficiently identify patients at risk of medication related hospitalization so tha ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. A new generation of targeted therapeutics for the treatment of cancer

    SBC: NERX BIOSCIENCES, INC.            Topic: NCI

    DESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical agents While the majority of these maybe innocuous those that damage DNA have severe consequences Thus the DNA damage response DDR and DNA repair in these tissues is extremely important The vast ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. An Immersive Virtual Reality Peer Support Application for Individuals with Opioid Use Disorder: Development and Initial Evaluation

    SBC: Very Real Help, LLC            Topic: NIDA

    PROJECT SUMMARY Drug overdoses are the leading cause of death in the United States with approximately 72,000 people dying from drug overdose in 2017. Many of these fatalities occurred in individuals with opioid use disorder (OUD), which is one of the greatest public health issues confronting the United States today. Digital Recovery Support Services (DRSs) that include peer support, psychoeducatio ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Probiotic Platform to Treat Necrotizing Enterocolitis

    SBC: Monon Bioventures LLC            Topic: 300

    PROJECT SUMMARY Probiotics hold enormous potential for promoting human health and treating disease One major hurdle to many probiotic products is their lack of persistence in the gut Monon Bioventures MBV and their research partners at the Research Institute at Nationwide Childrenandapos s Hospital RINCH are developing a novel enhanced tunable technology called ProNextTM that allows for a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. A Portable Device for Accurate Mouse Tail Vein Injection

    SBC: Technology Commercialization Partners LLC            Topic: OD

    PROJECT SUMMARYABSTRACT To datethe standard method to access a mouse tail vein is manual injectionbut its yield rate is poor in generalThis leads to multiple needle insertions associated with tissue damage and painBesidesfailure in tail vein injection leads to data lossand thereby more animals will be required to compensate itFinallythe dose variation induced by unreliable injection increases erro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A simple assay system for rapid detection of circulating tumor cells

    SBC: TELOVISION, LLC            Topic: NCI

    DESCRIPTION provided by applicant Metastasis or dissemination of primary tumor cells is the major cause of mortality in cancer patients Circulating tumor cells CTCs in the bloodstream are key players in the establishment of metastatic tumors Recent studies demonstrated that the number of CTCs present in patient blood directly correlate with cancer progression recurrence and survival rate ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Automated Rodent Research Home Cage Monitoring System for Animal Welfare

    SBC: Tricorder Array Technologies LLC            Topic: 100

    PROJECT SUMMARY The for profit small business concernTricorder Array Technologies LLCwill developin partnership with the University of Alabama at BirminghamSIDECAReSensing and Integrating Data for Environmental Conditions in Animal ResearchThis device will automate collection of relevant data that will enhance consistency in animal models used to study human health treatment researchOur innovative ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Biodegradability and Biocompatibility of a Shape Memory Polymer Wrap to Improve Saphenous Vein Graft Patency in Peripheral and Coronary Artery Bypass Grafting Surgeries

    SBC: VenoStent, Inc.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT Peripheral artery disease (PAD) affects nearly 12 million people in the United States. One of the most common surgical therapies is peripheral artery bypass grafting (PABG). Some patients are eligible for less invasive treatment options like angioplasty, but patients with calcified lesions are not. In patients that do receive PABG, approximately 20% fail within the first y ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government